RU2016123169A - Твердые композиции триглицеридов и их применение - Google Patents
Твердые композиции триглицеридов и их применение Download PDFInfo
- Publication number
- RU2016123169A RU2016123169A RU2016123169A RU2016123169A RU2016123169A RU 2016123169 A RU2016123169 A RU 2016123169A RU 2016123169 A RU2016123169 A RU 2016123169A RU 2016123169 A RU2016123169 A RU 2016123169A RU 2016123169 A RU2016123169 A RU 2016123169A
- Authority
- RU
- Russia
- Prior art keywords
- less
- composition according
- poly
- solid composition
- solid
- Prior art date
Links
- 239000007787 solid Substances 0.000 title claims 22
- 239000000203 mixture Substances 0.000 title claims 10
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 title claims 3
- 239000008247 solid mixture Substances 0.000 claims 51
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 20
- 239000013543 active substance Substances 0.000 claims 17
- 235000014113 dietary fatty acids Nutrition 0.000 claims 16
- 229930195729 fatty acid Natural products 0.000 claims 16
- 239000000194 fatty acid Substances 0.000 claims 16
- 150000004665 fatty acids Chemical class 0.000 claims 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 15
- 150000003626 triacylglycerols Chemical class 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 229920000642 polymer Polymers 0.000 claims 11
- PJHKBYALYHRYSK-UHFFFAOYSA-N triheptanoin Chemical compound CCCCCCC(=O)OCC(OC(=O)CCCCCC)COC(=O)CCCCCC PJHKBYALYHRYSK-UHFFFAOYSA-N 0.000 claims 11
- 229940078561 triheptanoin Drugs 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 9
- 125000004432 carbon atom Chemical group C* 0.000 claims 8
- 239000002245 particle Substances 0.000 claims 7
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 6
- 239000005977 Ethylene Substances 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 229920003176 water-insoluble polymer Polymers 0.000 claims 6
- 239000002253 acid Substances 0.000 claims 5
- 229920002301 cellulose acetate Polymers 0.000 claims 5
- 238000013268 sustained release Methods 0.000 claims 5
- 239000012730 sustained-release form Substances 0.000 claims 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 4
- 150000007513 acids Chemical class 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 230000003111 delayed effect Effects 0.000 claims 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- 102000003925 1,4-alpha-Glucan Branching Enzyme Human genes 0.000 claims 2
- 108090000344 1,4-alpha-Glucan Branching Enzyme Proteins 0.000 claims 2
- OZCMOJQQLBXBKI-UHFFFAOYSA-N 1-ethenoxy-2-methylpropane Chemical compound CC(C)COC=C OZCMOJQQLBXBKI-UHFFFAOYSA-N 0.000 claims 2
- 229910018072 Al 2 O 3 Inorganic materials 0.000 claims 2
- 102000002666 Carnitine O-palmitoyltransferase Human genes 0.000 claims 2
- 108010018424 Carnitine O-palmitoyltransferase Proteins 0.000 claims 2
- 229920008347 Cellulose acetate propionate Polymers 0.000 claims 2
- DQEFEBPAPFSJLV-UHFFFAOYSA-N Cellulose propionate Chemical compound CCC(=O)OCC1OC(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C1OC1C(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C(COC(=O)CC)O1 DQEFEBPAPFSJLV-UHFFFAOYSA-N 0.000 claims 2
- 229920002284 Cellulose triacetate Polymers 0.000 claims 2
- 239000001856 Ethyl cellulose Substances 0.000 claims 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical group CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 2
- 229920002527 Glycogen Polymers 0.000 claims 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 claims 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 2
- 229920001305 Poly(isodecyl(meth)acrylate) Polymers 0.000 claims 2
- 229920002319 Poly(methyl acrylate) Polymers 0.000 claims 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 2
- 229910004298 SiO 2 Inorganic materials 0.000 claims 2
- 229910010413 TiO 2 Inorganic materials 0.000 claims 2
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 claims 2
- 238000009825 accumulation Methods 0.000 claims 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims 2
- GAMPNQJDUFQVQO-UHFFFAOYSA-N acetic acid;phthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O GAMPNQJDUFQVQO-UHFFFAOYSA-N 0.000 claims 2
- 229920002678 cellulose Polymers 0.000 claims 2
- 239000001913 cellulose Substances 0.000 claims 2
- 229920006217 cellulose acetate butyrate Polymers 0.000 claims 2
- 229920006218 cellulose propionate Polymers 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims 2
- 229920001249 ethyl cellulose Polymers 0.000 claims 2
- 229910021485 fumed silica Inorganic materials 0.000 claims 2
- ZSDBFLMJVAGKOU-UHFFFAOYSA-N glycerol phenylbutyrate Chemical compound C=1C=CC=CC=1CCCC(=O)OCC(OC(=O)CCCC=1C=CC=CC=1)COC(=O)CCCC1=CC=CC=C1 ZSDBFLMJVAGKOU-UHFFFAOYSA-N 0.000 claims 2
- 229960002815 glycerol phenylbutyrate Drugs 0.000 claims 2
- 229940096919 glycogen Drugs 0.000 claims 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims 2
- 230000003647 oxidation Effects 0.000 claims 2
- 238000007254 oxidation reaction Methods 0.000 claims 2
- 229920001490 poly(butyl methacrylate) polymer Polymers 0.000 claims 2
- 229920001483 poly(ethyl methacrylate) polymer Polymers 0.000 claims 2
- 229920000212 poly(isobutyl acrylate) Polymers 0.000 claims 2
- 229920000205 poly(isobutyl methacrylate) Polymers 0.000 claims 2
- 229920000196 poly(lauryl methacrylate) Polymers 0.000 claims 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims 2
- 229920000184 poly(octadecyl acrylate) Polymers 0.000 claims 2
- 229920000139 polyethylene terephthalate Polymers 0.000 claims 2
- 239000005020 polyethylene terephthalate Substances 0.000 claims 2
- 229920000129 polyhexylmethacrylate Polymers 0.000 claims 2
- 229920000197 polyisopropyl acrylate Polymers 0.000 claims 2
- 239000004926 polymethyl methacrylate Substances 0.000 claims 2
- 229920000182 polyphenyl methacrylate Polymers 0.000 claims 2
- 229920001155 polypropylene Polymers 0.000 claims 2
- -1 polypropylene methyl acetate Polymers 0.000 claims 2
- 239000004814 polyurethane Substances 0.000 claims 2
- 229920002635 polyurethane Polymers 0.000 claims 2
- 239000011118 polyvinyl acetate Substances 0.000 claims 2
- 229920002689 polyvinyl acetate Polymers 0.000 claims 2
- 239000004800 polyvinyl chloride Substances 0.000 claims 2
- 229920000915 polyvinyl chloride Polymers 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- 239000010457 zeolite Substances 0.000 claims 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 1
- 108010001058 Acyl-CoA Dehydrogenase Proteins 0.000 claims 1
- 102000002735 Acyl-CoA Dehydrogenase Human genes 0.000 claims 1
- UIERETOOQGIECD-UHFFFAOYSA-N Angelic acid Natural products CC=C(C)C(O)=O UIERETOOQGIECD-UHFFFAOYSA-N 0.000 claims 1
- 108010068197 Butyryl-CoA Dehydrogenase Proteins 0.000 claims 1
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 claims 1
- 229920001503 Glucan Polymers 0.000 claims 1
- 108091052347 Glucose transporter family Proteins 0.000 claims 1
- 102100029492 Glycogen phosphorylase, muscle form Human genes 0.000 claims 1
- 208000028547 Inborn Urea Cycle disease Diseases 0.000 claims 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 claims 1
- 201000002169 Mitochondrial myopathy Diseases 0.000 claims 1
- 108010049717 Muscle Form Glycogen Phosphorylase Proteins 0.000 claims 1
- 102000001105 Phosphofructokinases Human genes 0.000 claims 1
- 108010069341 Phosphofructokinases Proteins 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 claims 1
- 229940072056 alginate Drugs 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- 108010028144 alpha-Glucosidases Proteins 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- 208000007386 hepatic encephalopathy Diseases 0.000 claims 1
- 150000001261 hydroxy acids Chemical class 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 239000012535 impurity Substances 0.000 claims 1
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 claims 1
- 230000002438 mitochondrial effect Effects 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 238000001694 spray drying Methods 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 208000030954 urea cycle disease Diseases 0.000 claims 1
- 150000004669 very long chain fatty acids Chemical class 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Botany (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Fats And Perfumes (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Fodder In General (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361904369P | 2013-11-14 | 2013-11-14 | |
| US61/904,369 | 2013-11-14 | ||
| PCT/US2014/065693 WO2015073816A1 (en) | 2013-11-14 | 2014-11-14 | Solid compositions of triglycerides and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2016123169A true RU2016123169A (ru) | 2017-12-19 |
Family
ID=53058066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016123169A RU2016123169A (ru) | 2013-11-14 | 2014-11-14 | Твердые композиции триглицеридов и их применение |
Country Status (18)
| Country | Link |
|---|---|
| US (6) | US20160243071A1 (enExample) |
| EP (2) | EP3068383B1 (enExample) |
| JP (4) | JP2017501972A (enExample) |
| KR (1) | KR102291310B1 (enExample) |
| CN (2) | CN113181158A (enExample) |
| AR (2) | AR099353A1 (enExample) |
| AU (1) | AU2014348470B2 (enExample) |
| CA (2) | CA3197154A1 (enExample) |
| CL (1) | CL2016001130A1 (enExample) |
| ES (1) | ES2833294T3 (enExample) |
| IL (1) | IL245588B (enExample) |
| MX (2) | MX383005B (enExample) |
| MY (1) | MY177028A (enExample) |
| PE (1) | PE20161024A1 (enExample) |
| PH (1) | PH12016500821A1 (enExample) |
| RU (1) | RU2016123169A (enExample) |
| TW (1) | TWI640327B (enExample) |
| WO (1) | WO2015073816A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX383005B (es) * | 2013-11-14 | 2025-03-13 | Ultragenyx Pharmaceutical Inc | Composiciones solidas de trigliceridos y usos de estas. |
| US20190076383A1 (en) * | 2017-09-08 | 2019-03-14 | Horizon Therapeutics, Llc | Methods for treating urea cycle disorders |
| US12419852B2 (en) | 2018-08-27 | 2025-09-23 | Exerkine Corporation | Method for treating lysosomal storage disease |
| US11583542B2 (en) | 2019-12-16 | 2023-02-21 | Amylyx Pharmaceuticals, Inc. | Compositions of bile acids and phenylbutyrate compounds |
| CN113476408A (zh) * | 2021-07-23 | 2021-10-08 | 兆科药业（广州）有限公司 | 一种苯丁酸甘油酯颗粒剂及其制备方法与应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2800610B2 (ja) * | 1992-12-15 | 1998-09-21 | 不二製油株式会社 | 水中油型乳化物の製造法 |
| JP3522843B2 (ja) * | 1994-07-29 | 2004-04-26 | 昭和産業株式会社 | リポ製剤 |
| CA2212047C (en) * | 1995-02-07 | 2010-11-16 | Saul W. Brusilow | Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders |
| JPH08311480A (ja) * | 1995-05-18 | 1996-11-26 | D H Ee Kodo Seisei Chushutsu Gijutsu Kenkyu Kumiai | 高純度トリアシルグリセロールからなる油脂の製造方法及び高度不飽和脂肪酸含有油脂組成物 |
| NZ513329A (en) * | 1999-02-05 | 2003-11-28 | Baylor University Medical Ct | Nutritional supplement or pharmaceutical preparation comprising triglycerides with seven-carbon fatty acid |
| US8399515B2 (en) * | 2003-05-20 | 2013-03-19 | Baylor Research Institute | Five and fifteen carbon fatty acids for treating metabolic disorders and as nutritional supplements |
| US20050058673A1 (en) * | 2003-09-09 | 2005-03-17 | 3M Innovative Properties Company | Antimicrobial compositions and methods |
| US7141114B2 (en) * | 2004-06-30 | 2006-11-28 | Rec Silicon Inc | Process for producing a crystalline silicon ingot |
| CA2573054C (en) | 2004-07-02 | 2012-10-09 | Baylor Research Institute | Glycogen or polysaccharide storage disease treatment method |
| CA2599667C (en) * | 2005-03-10 | 2014-12-16 | 3M Innovative Properties Company | Antimicrobial compositions comprising esters of hydroxy carboxylic acids |
| CN101137359B (zh) * | 2005-03-10 | 2011-01-12 | 3M创新有限公司 | 治疗耳感染的方法 |
| JP2009525992A (ja) * | 2006-02-10 | 2009-07-16 | スポーツコム デンマーク アプス | コーティングを施した錠剤、その製造方法、及び関連する使用 |
| JP5296366B2 (ja) * | 2007-10-29 | 2013-09-25 | 日清オイリオグループ株式会社 | 医薬品用持久力向上剤および持久力向上用医薬品 |
| US8642012B2 (en) | 2008-04-29 | 2014-02-04 | Hyperion Therapeutics, Inc. | Methods of treatment using ammonia-scavenging drugs |
| WO2011159634A1 (en) * | 2010-06-14 | 2011-12-22 | Baylor Research Institute | Triheptanoin diet for adult polyglucosan body disease (apbd) treatment |
| CN101919453B (zh) * | 2010-08-16 | 2013-04-10 | 苏州市佳禾食品工业有限公司 | 中碳链脂肪酸粉末油脂及其制备方法 |
| BR112014007357B1 (pt) | 2011-09-30 | 2022-12-06 | Immedica Pharma Ab | Método para determinar o ajuste da dosagem de um fármaco de varredura de nitrogênio |
| TWI572352B (zh) * | 2012-03-01 | 2017-03-01 | 波麥堤克藥學Ｓｍｔ有限公司 | 用於製備具中鏈長度之脂肪酸的三酸甘油酯之方法 |
| WO2013158616A1 (en) | 2012-04-16 | 2013-10-24 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Treatment of medium-chain acyl-coa dehydrogenase deficiency |
| CN104955450A (zh) | 2012-12-13 | 2015-09-30 | 达拉斯贝勒研究院 | 用于治疗葡萄糖转运体1缺乏症的三庚酸甘油酯 |
| MX383005B (es) * | 2013-11-14 | 2025-03-13 | Ultragenyx Pharmaceutical Inc | Composiciones solidas de trigliceridos y usos de estas. |
-
2014
- 2014-11-14 MX MX2016006329A patent/MX383005B/es unknown
- 2014-11-14 PE PE2016000621A patent/PE20161024A1/es not_active Application Discontinuation
- 2014-11-14 CN CN202110316004.0A patent/CN113181158A/zh active Pending
- 2014-11-14 RU RU2016123169A patent/RU2016123169A/ru unknown
- 2014-11-14 US US14/419,601 patent/US20160243071A1/en not_active Abandoned
- 2014-11-14 EP EP14861440.7A patent/EP3068383B1/en active Active
- 2014-11-14 CA CA3197154A patent/CA3197154A1/en active Pending
- 2014-11-14 KR KR1020167013964A patent/KR102291310B1/ko active Active
- 2014-11-14 ES ES14861440T patent/ES2833294T3/es active Active
- 2014-11-14 JP JP2016529444A patent/JP2017501972A/ja active Pending
- 2014-11-14 AU AU2014348470A patent/AU2014348470B2/en active Active
- 2014-11-14 AR ARP140104294A patent/AR099353A1/es not_active Application Discontinuation
- 2014-11-14 MY MYPI2016000861A patent/MY177028A/en unknown
- 2014-11-14 EP EP20196269.3A patent/EP3782610A1/en active Pending
- 2014-11-14 WO PCT/US2014/065693 patent/WO2015073816A1/en not_active Ceased
- 2014-11-14 CA CA2929688A patent/CA2929688C/en active Active
- 2014-11-14 CN CN201480064471.7A patent/CN105764497A/zh active Pending
- 2014-11-14 TW TW103139665A patent/TWI640327B/zh active
-
2016
- 2016-05-03 PH PH12016500821A patent/PH12016500821A1/en unknown
- 2016-05-10 IL IL245588A patent/IL245588B/en unknown
- 2016-05-11 CL CL2016001130A patent/CL2016001130A1/es unknown
- 2016-05-13 MX MX2021001790A patent/MX2021001790A/es unknown
-
2019
- 2019-06-19 US US16/445,557 patent/US20200069631A1/en not_active Abandoned
-
2020
- 2020-03-11 JP JP2020041943A patent/JP2020111585A/ja active Pending
-
2022
- 2022-05-16 JP JP2022080251A patent/JP2022107017A/ja active Pending
-
2023
- 2023-02-10 US US18/167,551 patent/US20230181513A1/en active Pending
- 2023-10-03 AR ARP230102641A patent/AR130666A2/es unknown
-
2024
- 2024-07-02 JP JP2024106876A patent/JP2024129109A/ja active Pending
- 2024-12-26 US US19/002,257 patent/US20250120936A1/en active Pending
- 2024-12-26 US US19/002,217 patent/US20250120934A1/en active Pending
- 2024-12-26 US US19/002,233 patent/US20250120935A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016123169A (ru) | Твердые композиции триглицеридов и их применение | |
| KR101413339B1 (ko) | 폴리불포화 지방산의 알킬 에스테르에 현탁된 스타틴의마이크로캡슐을 포함하는 약학 조성물 | |
| TWI571271B (zh) | 包含ω－３脂肪酸酯及ＨＭＧ－ＣｏＡ還原酶抑制劑之口服複合組成物 | |
| CA2540984A1 (en) | A solid dosage form comprising a fibrate | |
| RU2612022C2 (ru) | Фармацевтические композиции | |
| FR2698560A1 (fr) | Principes actifs pulvérulents stabilisés, compositions les contenant, leur procédé d'obtention et leurs applications. | |
| CA2799407A1 (fr) | Forme pharmaceutique orale alcoolo-resistante | |
| CN109996452A (zh) | 粉末状配制物 | |
| JP2017501972A5 (enExample) | ||
| JP2016501248A5 (enExample) | ||
| US20230148650A1 (en) | Novel coating composition and coated compositions comprising the same | |
| WO2012014052A4 (en) | Novel coated extended release pharmaceutical compositions containing paliperidone | |
| JP6148510B2 (ja) | ソホロリピッド含有粉末組成物 | |
| US9200164B2 (en) | Coating system | |
| JP2022000013A (ja) | 新規コーティング系（ｉｉ） | |
| KR20220119374A (ko) | 결정질 형태의 코팅 매트릭스로 위보호된 과립형 박테리아, 이의 제조 방법 및 이의 조성물 | |
| TW201138862A (en) | Beta-blocking active ingredient capsules and polyunsaturated fatty acid esters | |
| HK40056892A (en) | Solid compositions of triglycerides and uses thereof | |
| CN103417507B (zh) | 布地奈德药物组合物 | |
| WO2023120558A1 (ja) | 還元型補酵素ｑ１０の保存方法 | |
| WO2021023850A1 (en) | Method of preparing a solid dosage form and a binder | |
| CA2943021A1 (en) | Solid formulations containing omega-3 and resveratrol |